Sanofi is seeking initial bids for its $20B consumer health arm as the company moves ahead with preparations for a potential listing of the arm, Bloomberg’s Pamela Barbaglia, Dinesh Nair, Francesca Veronesi, and Swetha Gopinath report. The drugmaker has asked potential suitors to make first-round bids by mid-July, according to people familiar with the matter. Advent International and France’s PAI Partners are seen as the most keen on the asset, the people say.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi a winner from ‘highly impressive’ Alnylam data, says Citi
- Sanofi, Biovac spearhead polio vaccine manufacturing capabilities in Africa
- Innate Pharma announces updated results from SAR443579/IPH6101
- Novavax price target raised to $18 from $12 at BofA
- Sanofi’s Dupixent Awaits Extended FDA Review